0000000000203525

AUTHOR

Roberta Sanfilippo

showing 4 related works from this author

Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, retrospective, multicenter study of the italian sarcoma group

2021

The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with ≥1 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1–40), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior (p &lt

0301 basic medicineLeiomyosarcomaCancer Researchmedicine.medical_specialtyDacarbazinelcsh:RC254-282GastroenterologyArticlePazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalObservationalTrabectedinSoft tissue sarcomaPerformance statusbusiness.industrySoft tissue sarcomaReal-lifelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisSarcomabusinessmedicine.drugTrabectedin
researchProduct

Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.

2016

11062Background: Human equilibrative nucleoside transporter 1 (hENT1) is the major gemcitabine transporter into cells. Gemcitabine is an active drug in different sarcoma subtypes including leiomyos...

LeiomyosarcomaDrugCancer Researchbiologybusiness.industrymedia_common.quotation_subjectTransporterEquilibrative nucleoside transporter 1medicine.diseaseGemcitabineOncologybiology.proteinCancer researchMedicineAngiosarcomaSarcomabusinessmedicine.drugmedia_commonJournal of Clinical Oncology
researchProduct

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma

2017

Background: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. Since gemcitabine is widely used in the treatment of leiomyosarcoma and angiosarcoma, we investigated the correlation between hENT1 expression and gemcitabine efficacy in these sarcoma subtypes.Methods: We retrospectively identified 71 patients affected by advanced angiosarcoma (26) or leiomyosarcoma (45) treated within five Italian referral centres for sarcoma; among them, 49 patients (15 angiosarcoma, 34 leiomyosarcoma) were treated…

0301 basic medicineOncologyLeiomyosarcomaMalePathologyCancer ResearchGene ExpressionKaplan-Meier EstimateEquilibrative nucleoside transporter 1Deoxycytidine0302 clinical medicineRetrospective StudieMedicineAngiosarcomaAged 80 and overPredictive markerbiologygemcitabineMiddle AgedSurvival RateOncology030220 oncology & carcinogenesishuman equilibrative nucleoside transporter 1; gemcitabine; leiomyosarcoma; angiosarcomaFemaleSarcomamedicine.drugHumanLeiomyosarcomaAdultmedicine.medical_specialtyAntimetabolites AntineoplasticHemangiosarcomahuman equilibrative nucleoside transporter 1; gemcitabine; leiomyosarcoma; angiosarcoma; Adult; Aged; Aged 80 and over; Antimetabolites Antineoplastic; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Oncology; Cancer ResearchDisease-Free Survivalhuman equilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 103 medical and health sciencesInternal medicinePancreatic cancerHumansSurvival rateRetrospective StudiesAgedangiosarcomabusiness.industrymedicine.diseaseGemcitabine030104 developmental biologybiology.proteinTranslational Therapeuticsbusiness
researchProduct

Role of Microbiota in development, gene expression and epigenetic modifications in D. melanogaster host model

Eukaryotes and prokaryotes have developed mutually beneficial relationships over millennia of evolutionary adaptation. Recent observations suggest a strong correlation between the presence of Microbiota and host homeostasis, but little is known about the mechanisms they use to shape the physiology and to reprogram gene expression of their host. Using both conventionally reared and germ-free D. melanogaster as a model system, I found a role of bacteria in host protein expression and development, as germ-free flies develop more slowly than their conventional counterpart. Remarkably, using the classic variegated In(1)wm4 inversion, I identified a role of Microbiota as modifier of white Positio…

Microbiota epigenetics NGS PEV
researchProduct